119-S-272 DC Insider Whip Count Analysis

Status and institutional context

- Senate passed S. 272 (Protect Infant Formula from Contamination Act) by unanimous consent on April 28, 2026; message was transmitted to the House shortly thereafter per standard process and bill trackers. Sponsor: Sen. Gary Peters (D‑MI). (govinfo.gov)

• Senate HELP (Chair: Sen. Bill Cassidy, R‑LA) reported a bipartisan substitute; committee action recorded 22–0 before floor passage. (help.senate.gov)
• Current leadership landscape: Senate Majority Leader John Thune (R‑SD); House Speaker Mike Johnson (R‑LA); House Majority Leader Steve Scalise (R‑LA); House Democratic Leader Hakeem Jeffries (D‑NY). (senate.gov)
• House party balance is very narrow, increasing leadership’s reliance on bipartisan suspension votes for noncontroversial items. (radiotv.house.gov)
• Policy backdrop: FDA’s long‑term infant formula resiliency strategy (Jan. 2025) and recent FDA testing updates (April 2026) keep safety and supply on the front burner—creating a favorable, low‑salience environment for a targeted process bill. (fda.gov)

Breakdown: expected support/opposition

Grounded in recent votes, committee rosters, and leadership incentives.

• Senate: Effectively unanimous (UC). Bipartisan pedigree: sponsor Peters; nine bipartisan cosponsors; HELP reported a substitute; then UC passage. Expect full Republican conference plus Democrats to support any House‑tuned text in a conference, if needed. (congress.gov)
• House Republicans: Leadership and relevant chairs have been running FDA/food‑safety hearings; E&C Full Chair Brett Guthrie and Health Subcommittee Chair Morgan Griffith have teed up related food‑safety/infant‑nutrition measures, signaling readiness to move a narrow FDA process bill. Expect broad but not perfectly unanimous GOP support; a small anti‑regulatory bloc could register no votes. (congress.gov)
• House Democrats: Likely near‑unanimous yes. The caucus has consistently pressed for stronger infant‑food oversight; Dem members are active on E&C Health and have promoted companion concepts (e.g., INFANTS Act) in recent hearings. They can easily supply votes to clear a Suspension threshold. (energycommerce.house.gov)
• Interest groups/signalers: Consumer‑protection voices and child‑health advocates have pushed for stronger testing/notification regimes; FDA has spotlighted ongoing testing and industry best‑practice work with the Infant Nutrition Council of America—environment that reduces organized opposition to a notifications/reporting bill. (fda.gov)

Key legislators and leverage points

Who can speed this up—or slow it down—given current roles.

• Speaker Mike Johnson (R‑LA): decides whether S. 272 runs on the Suspension Calendar (2/3 needed) or via a rule (simple majority). Narrow majority + low controversy point to Suspension. (mikejohnson.house.gov)
• Majority Leader Steve Scalise (R‑LA): floor time gatekeeper; can place it on a Monday/Tuesday Suspension block to minimize friction. (radiotv.house.gov)
• Rules Chair Virginia Foxx (R‑NC): relevant only if leadership opts for a special rule; otherwise minimal role under Suspension. (rules.house.gov)
• E&C Chair Brett Guthrie (R‑KY): primary House authorizing gate; can move a quick clean markup of the Senate bill or waive markup and bless a Suspension path. (congress.gov)
• E&C Health Subcommittee Chair Morgan Griffith (R‑VA): running FDA foods/infant‑nutrition content; his docket provides policy cover and technical vetting. (energycommerce.house.gov)
• Democratic Leader Hakeem Jeffries (D‑NY): can deliver the Democratic votes needed to clear a Suspension margin if several Republicans defect. (democraticleader.house.gov)
• Senate HELP Chair Bill Cassidy (R‑LA): already delivered a 22–0 markup—his posture deters Senate‑side turbulence if the bill returns with minor House touches. (help.senate.gov)

Leadership stance and procedural dynamics

• The Senate has already optimized the text (committee substitute) and demonstrated no floor resistance (UC). That lowers inter‑chamber risk if the House passes the Senate bill clean. (govinfo.gov)
• Most probable House path: Suspension of the Rules—a 40‑minute debate, no amendments, two‑thirds threshold. It’s the standard vehicle for narrow, bipartisan authorizing fixes like this when margins are tight. (Leadership references above.) (mikejohnson.house.gov)
• If leadership wants policy tweaks from ongoing E&C work on infant formula/food safety, Guthrie/Griffith can mark up a modest amendment; but that would require the Senate to take another look. Given Senate UC, clean passage is the faster play. (energycommerce.house.gov)
• Issue climate helps: FDA’s January 2025 strategy and April 2026 testing updates keep infant‑formula safety salient without raising ideological flags—useful cover for a fast, bipartisan floor move. (fda.gov)
• House majority is razor‑thin; leadership routinely leans on bipartisan Suspension votes for uncontroversial items. Expect Dems to provide cushion if a few hard‑right members object to perceived FDA expansions. (radiotv.house.gov)

Assessment

Bottom line, with explicit confidence rating.

Likelihood of House passage: high (confidence: high). Rationale: unanimous Senate passage after a 22–0 HELP markup; active House E&C focus on FDA food safety; narrow but manageable House margins under Suspension when Democrats support safety/oversight measures. Timing is at leadership’s discretion and could be achieved on an early‑week Suspension block in May. (govinfo.gov)

Sourcing highlights

Selected, verifiable anchors used for this whip count.

• Senate floor action (UC, April 28, 2026), and committee amendment text in the Congressional Record. (govinfo.gov)
• Congress.gov docket: sponsor/cosponsors; reported text and calendar history. (congress.gov)
• HELP Chair confirmation; 22–0 markup reference. (help.senate.gov)
• House E&C Chair Guthrie (full committee) and Health Subcommittee Chair Griffith activity on FDA/food safety. (congress.gov)
• House leadership/party balance references. (mikejohnson.house.gov)
• FDA strategic/reporting backdrop informing salience. (fda.gov)
• Tracker note that Senate message was sent to the House post‑passage. (legiscan.com)